TREATMENT OF INTRAUTERINE GROWTH RESTRICTION WITH LOW MOLECULAR WEIGHT HEPARIN: RANDOMIZED CLINICAL TRIAL (TRACIP STUDY) - TRACIP

Fundació Sant Joan de Déu0 个研究点目标入组 50 人开始时间: 2017年7月31日最近更新: 2017年10月30日

试验速览

暂无简介。

•Women older than 18 years.
•Unique gestations
•Diagnosis of early placental intrauterine growth (according to Delphi classification): <32 weeks at diagnosis + Doppler AU with absent / reverse flow or (estimated fetal weight <10 percentile + pulsed Doppler ultrasonography) or (estimated fetal weight • Patient giving written informed consent to participate in the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Chromosopathies, genetic alterations or fetal malformations.
•Diagnostic treatment with low molecular weight heparins, oral anticoagulants or acetylsalicylic acid prior to inclusion.
•History of heparin-induced thrombocytopenia.
•Active hemorrhage or increased risk of bleeding due to changes in hemostasis.
•Severe hepatic or pancreatic function disorder.
•Organic lesions that may bleed (eg, active peptic ulcer, hemorrhagic stroke, aneurysms, or brain tumors).

发起方